Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage

Therapeutic Apheresis and Dialysis

Volumn 11, Issue 2, 2007, Pages 107-113

  Oka, Yoshinari ^a   Miyazaki, Masashi ^a   Takatsu, Shigeko ^a   Kunitomo, Kei Ichi ^a   Uno, Futoshi ^b   Maruyama, Masanobu ^b   Matsuda, Hiroaki ^b  

^a Saiwai cho Memorial Hospital   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Bicarbonate; Hemodialysis; Metabolic acidosis; Non anion gap acidosis; Sevelamer hydrochloride

Indexed keywords

CALCIUM CARBONATE; SEVELAMER;

ADULT; ARTICLE; BICARBONATE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DOSE RESPONSE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERCHLOREMIA; HYPERPHOSPHATEMIA; MALE; METABOLIC ACIDOSIS; PH MEASUREMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; STUDENT T TEST;

ACIDOSIS; BICARBONATES; CHELATING AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; POLYAMINES; RENAL DIALYSIS;

EID: 33947399211     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2007.00432.x     Document Type: Article

References (13)

1. Edmung G, Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15:458-82.
2. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17.
3. Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52.
4. Chertow GM, Raggi P, McCarthy JT et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients.Am J Nephrol 2003;23:307-14.
5. Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004;19:1489-96.
6. Brezina B, Qunibi WY, Nolan CR. Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int 2004;66:39-45.
7. Macroui A, Sonikian MA, Pani IT et al. Metabolic acidosis aggravation and hyperkalemia in hemodialysis patients treated by sevelamer hydrochloride. Ren Fail 2005;27:143-7.
8. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:12-28.
9. Bommer J, Locatelli F, Satayathum S et al. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:661-71.
10. Marco MP, Muray S, Betriu A, Craver L, Belart M, Fernandez E. Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients. Nephron 2002;92:499-500.
11. Gallieni M, Cozzolino M, Brancaccio D. Transient decrease of serum bicarbonate levels with Sevelamer hydrochloride as the phosphate binder. Kidney Int 2000;57:1776-7.
12. Koiwa F, Onoda N, Kato H et al. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial 2005;9:340-6.
13. Qunibi WY, Hootkins RE, McDowell LL et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004;65:1914-26.